Suggested remit: To appraise the clinical and cost effectiveness of nivolumab in combination with chemotherapy within its marketing authorisation for untreated advanced gastric or gastro-oesophageal junction cancer.
 
Status In progress
Process STA 2018
ID number 1465

Provisional Schedule

Committee meeting: 2 15 February 2022
Expected publication 27 April 2022

Project Team

Project lead Thomas Feist

Email enquiries

Consultees

Companies sponsors Bristol-Myers Squibb
Others Department of Health and Social Care
  Welsh Government
Professional groups Association of Cancer Physician
  Cancer UK
  Royal College of Pathologists
  Royal College of Physicians
  Royal College of Radiologists

Commentators

General commentators All Wales Therapeutics and Toxicology Centre
  British National Formulary
  Department of Health, Social Services and Public Safety for Northern Ireland
  Medicines and Healthcare products Regulatory Agency
  Scottish Medicines Consortium
Relevant research groups Institute of Cancer Research

Timeline

Key events during the development of the guidance:

Date Update
21 October 2021 - 11 November 2021 Appraisal consultation
26 April 2021 Invitation to participate
12 October 2020 - 02 November 2020 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 2
15 June 2020 The Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer. Please note that following on from information received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-November 2020 when we will write to you about how you can get involved
29 August 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-August 2020 when we will write to you about how you can get involved.
21 June 2019 As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer. Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid-October 2019 when we will write to you about how you can get involved.
22 March 2019 In progress. As you will be aware, the Department for Health and Social Care has asked NICE to conduct an appraisal of Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction Please note that following on from advice received from the company the timelines for this appraisal have been revised. We now anticipate that the appraisal will begin during mid July 2019 when we will write to you about how you can get involved.
17 January 2019 - 14 February 2019 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
24 April 2018 Referral
24 April 2018 In progress. Topic referred

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance